                          AIDS Daily Summary
                            March 3, 1995


The Centers for Disease Control and Prevention (CDC) National AIDS
Clearinghouse makes available the following information as a public
service only. Providing this information does not constitute endorsement
by the CDC, the CDC Clearinghouse, or any other organization. Reproduction
of this text is encouraged; however, copies may not be sold, and the CDC
Clearinghouse should be cited as the source of this information.
Copyright 1995, Information, Inc., Bethesda, MD


************************************************************
"TB Infection Reported on Airline Flight"
"Baltimore Needle Exchange Surpasses Projected Service"
"Republicans Agree to Back Restoration of Some Cuts"
"Second FDA-Approved AIDS Treatment Study Begins"
"In Final Plan, Pataki Sticks to Theme of Cuts"
"Across the USA: Florida"
"Second International Conference on Engineered Vaccines for 
Cancer and AIDS"
"The Use of Unconventional Remedies among HIV-Positive Men Living
in California"
"Labor Women Pledge to Work Together in HIV/AIDS Battle"
"'Male Cancer'--a Female Cure?"
************************************************************

"TB Infection Reported on Airline Flight"
Washington Post (03/03/95) P. A3
     Officials from the Centers for Disease Control and Prevention 
(CDC) on Thursday reported the first instance of tuberculosis 
(TB) transmission between airline passengers.  The agency 
cautioned that people who have infectious TB should not be 
allowed on commercial flights.  Four people contracted TB while 
seated near an infectious passenger on a domestic flight last 
year.  Alan Hinman, a senior adviser to the CDC director, said 
that if people with infectious TB "need to travel, they should 
travel by private auto or air ambulance...or postpone travel 
until they have been treated to the extent that they are no 
longer infectious."  He added that none of the passengers who 
were infected as the result of exposure have developed disease.  
The passengers were advised to receive preventive therapy to 
reduce the risk that they would ever develop the disease.  Most 
people with active tuberculosis are infectious when diagnosed, 
but become noninfectious within weeks of treatment.  Related 
Stories: New York Times (03/03) P. B7; Baltimore Sun (03/03) P. 
12A; Philadelphia Inquirer (03/03) P. A7
      
"Baltimore Needle Exchange Surpasses Projected Service"
Baltimore Sun (03/03/95) P. 4B;  Morris, John A.
     Last year, in an attempt to slow the spread of AIDS, the Maryland
legislature approved a three-year pilot needle exchange program 
for Baltimore.  The program has already served four times the 
number of people anticipated, but because HIV takes about six 
months to incubate, it is too early to know whether the program 
will halt the spread of AIDS, said Dr. Peter L. Beilinson, 
Baltimore's health commissioner, on Thursday.  Since it began at 
two locations in Baltimore last August, the program has served 
2,000 drug users.  Beilinson said he believes the program will 
serve more than 3,500 addicts in its first year.  "We're at the 
point where we could expand to other sites," he said, noting that
there are more than 35,000 injection drug users in Baltimore.  
Related Story: USA Today (03/03) P. 6A
      
"Republicans Agree to Back Restoration of Some Cuts"
New York Times (03/03/95) P. A19;  Gray, Jerry
     The Republican majority on the House Appropriations Committee 
decided on Thursday to reinstate millions of dollars cut from 
social programs such as AIDS prevention.  The committee approved 
an amendment proposed by Rep. Nancy Pelosi (D.-Calif.) to restore
$36 million for AIDS care and prevention programs--$13 million 
for the Ryan White Care Act and $23 million for an HIV prevention
program by the Centers for Disease Control and Prevention.  "You 
do not want to go home to explain a no vote on this matter," 
Pelosi warned the panel.
      
"Second FDA-Approved AIDS Treatment Study Begins"
PR Newswire (03/02/95)
     Biocontrol Technology, Inc. announced on Thursday that its IDI, 
Inc. subsidiary had commenced its second clinical trial of a 
hyperthermia treatment for AIDS patients.  The study, which began
at St. Elizabeth Hospital in Lafayette, Ind., on Feb. 15, will be
conducted with the help of HemoCleanse, Inc.  Whole-body 
extracorporeal hyperthermia treatment combats HIV, which is heat 
sensitive, by artificially inducing fever.  Biocontrol CEO Fred 
E. Cooper said, "Although there can be no guarantees, because of 
the excellent results achieved in our July study, we expect equal
or better results from this study."
      
"In Final Plan, Pataki Sticks to Theme of Cuts"
New York Times (03/03/95) P. B6;  Dao, James
     On Thursday, New York Governor George E. Pataki released the 
final version of his state budget.  The final amendments to his 
proposal came after a month of protests against large cuts in the
spending plan for transportation, education, health, and social 
service programs.  Even on Thursday, 15 people calling for 
increased state spending on AIDS were arrested for disrupting a 
speech by Gov. Pataki to journalists and business leaders in 
Manhattan.  "Today's proposals build upon my commitment to cut 
taxes and spending by instituting sweeping fundamental reforms of
government," said Gov. Pataki in a statement.
      
"Across the USA: Florida"
USA Today (03/03/95) P. 6A
     The Florida Supreme Court has ruled that a man wrongly diagnosed 
as HIV-positive, and a couple given the wrong baby to bury cannot
collect damages for mental anguish.  The "impact rule" is 
applicable only when there are physical injuries, the jurists 
said.
      
"Second International Conference on Engineered Vaccines for 
Cancer and AIDS"
Business Wire (03/02/95)
     The Second International Conference on Engineered Vaccines for 
Cancer and AIDS is being held March 3-5 in San Francisco.  Topics
will include the results of human and primate trials of AIDS 
vaccines, gene therapy, and a number of strategies for designing 
AIDS and cancer vaccines.  Among the speakers attending the 
conference is internationally renowned AIDS researcher Dr. Jay A.
Levy, a professor of medicine at the University of California at 
San Francisco, who was one of the first to identify HIV and is a 
leader in the investigation of methods to boost the immune system
cells' ability to fight the virus.
      
"The Use of Unconventional Remedies among HIV-Positive Men Living
in California"
Journal of the Association of Nurses in AIDS Care (01/95-02/95) 
Vol. 6, No. 1, P. 17;  Dwyer, Johanna T.;  Salvato-Schille, 
Annette M.;  Coulston, Ann et al.
     Using a multiple-choice questionnaire, Dwyer et al. compared the 
use of and attitudes toward unconventional remedies among two 
groups of HIV-positive men in Northern California.  The first 
group was enrolled in clinical trial protocols for various 
National Institutes of Health-approved treatments for HIV 
infection at an AIDS Clinical Trials Unit (ACTU), while the 
comparison group consisted of a self-help group of patients at a 
community healthcare clinic in San Francisco.  Eighty-five 
percent of the study participants attending the community health 
center had used unconventional therapies, compared to 58 percent 
enrolled in the ACTU's clinical trial.  Altogether, 70 percent of
all participants had used unconventional remedies at least once. 
While 54 percent of the respondents said that AZT was the most 
useful treatment for their health problem, other remedies include
diet and nutrition counseling, acupuncture, Chinese herbs, and 
hypnosis.  The men enrolled in the clinical trial protocols for 
investigational drugs used unconventional remedies significantly 
less than the community health center participants, who were 
enrolled in an open trial of hypericin, an unproven treatment.
      
"Labor Women Pledge to Work Together in HIV/AIDS Battle"
Nation's Health (02/95) Vol. 25, No. 2, P. 24
     The National Labor Leaders' Conference on Women and HIV/AIDS, 
sponsored by the Centers for Disease Control and Prevention and 
the Coalition of Labor Union Women, concluded with participants 
pledging to join together to promote compassion and prevention 
efforts.  "We all have learned that we have to get over the 
ignorance, the fear, the stereotypes, and the apathy," said 
Gloria Johnson, president of the Coalition of Labor Union Women. 
At the end of the January conference, participants made plans to 
form a speakers' bureau to raise the issue of AIDS and HIV at all
labor gatherings.  Johnson is trying to put together an AIDS 
information clearinghouse as a resource for labor chapters across
the country.  Her goal is to help workers develop workplace 
policies on AIDS and provide more widespread prevention 
education.
      
"'Male Cancer'--a Female Cure?"
Longevity (03/95) Vol. 7, No. 4, P. 98;  Pfeiffer, Naomi
     Men who are infected with HIV often develop Kaposi's sarcoma 
(KS), a cancer characterized by dark blotches on the skin.  
HIV-positive women, however, rarely develop KS.  Scientists 
theorize that the protection may be due to female hormones, 
including human chorionic gonadotropin (HCG).  To determine 
whether the hormone also protects men, Dr. Parkash Gill of the 
University of Southern California is holding the first human 
trial of HCG in the United States.  If the trials are successful,
HCG will probably be used immediately to fight KS.
      
